Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial.

Am J Gastroenterol · 2024 · PMC12208385 · PMID 39787364

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The 3,200 mg dose seemed to show a favorable trend regarding change in FCP compared with placebo, but did not result in clinical remission or endoscopic improvement after 28 days of treatment.

also in 1,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.